Because of the limited chemotherapeutic approaches available to treat reactivated latent Toxoplasma gondii infection manifested as toxoplasmic encephalitis in AIDS patients, investigation of novel chemotherapeutic agents is warranted. Several poloxamers (nonionic block copolymers composed of a central hydrophobic chain of polyoxypropylene flanked by two hydrophilic chains of polyoxyethylene) were tested for their abilities to alter the course of acute infection with a highly virulent T. gondii in mice. The effect varied markedly with the length of the constituent chains of the copolymers. The most effective preparations were highly effective when administered after infection and afforded remarkable protection against 10 to 1,000 100%o lethal doses of T.
Because of the limited chemotherapeutic approaches available to treat reactivated latent Toxoplasma gondii infection manifested as toxoplasmic encephalitis in AIDS patients, investigation of novel chemotherapeutic agents is warranted. Several poloxamers (nonionic block copolymers composed of a central hydrophobic chain of polyoxypropylene flanked by two hydrophilic chains of polyoxyethylene) were tested for their abilities to alter the course of acute infection with a highly virulent T. gondii in mice. The effect varied markedly with the length of the constituent chains of the copolymers. The most effective preparations were highly effective when administered after infection and afforded remarkable protection against 10 to 1,000 100%o lethal doses of T.
gondii. Protection was dose dependent, and multiple treatments were more effective than single treatment. These preliminary findings warrant additional studies to determine whether this novel form of antitoxoplasma chemotherapy may prove promising in the treatment or prevention of acute toxoplasmic encephalitis in humans.
The prevalence of Toxoplasma gondii infection in humans varies greatly around the world, ranging from low levels to >90% in the adult populations of France and El Salvador (18) . In the United States, depending on location, 15 to 68% of the adults are infected with this obligate intracellular protozoan parasite. Once infected, these individuals harbor for life T. gondii cysts in their brains and skeletal and cardiac muscles. Although chronic toxoplasmosis is usually uneventful, reactivation of latent infection in the immunocompromised host (e.g., in transplant recipients upon immunosuppressive therapy or in patients with certain types of cancer or receiving immunosuppressive chemotherapeutic regimens) can be life threatening. Patients with AIDS who harbor a chronic T. gondii infection are also at risk owing to the presence of T. gondii cysts in the central nervous system (10, 13) . Evidence that at least 30% of AIDS patients seropositive for T. gondii will develop life-threatening recrudescent toxoplasmic encephalitis is accumulating (15) .
Current therapy for toxoplasmic encephalitis is a synergistic combination of pyrimethamine and sulfadiazine that inhibits the parasite's folate-metabolizing enzymes (1) . Because the diagnosis of toxoplasmic encephalitis requires immediate primary treatment followed by a life-long maintenance regimen of chemotherapy, drug toxicity is a major factor. Pyrimethamine treatment is associated with bone marrow toxicity requiring supplemental administration of folinic acid (3, 17) , and the sulfonamide component of the combination can also induce adverse drug reactions such as severe skin rashes, which seem to be exacerbated in AIDS patients (4, 12) . Withdrawal of maintenance therapy is associated with a toxoplasmic encephalitis relapse rate of approximately 80% (14, 15) . To complicate matters further, azidothymidine, the cornerstone of chemotherapy for AIDS, appears to antagonize the antitoxoplasma effects of py-rimethamine, as shown by in vitro and in vivo studies with mice (11) .
Clearly, a more effective and less toxic chemotherapeutic regimen for toxoplasmic encephalitis is required. The present study employed a mouse model of acute T. gondii infection and involved preliminary experiments on a novel group of poloxamers, some of which have been shown to be effective adjuvants (7, 8, 22) (16, 19) (Fig. 1) buffered saline, and warmed to room temperature before injection.
Because the unformulated poloxamers tend to form emulsions as they warm (16, 19) , a formulation of CRL-8131 that would stabilize the emulsion was developed. CRL-8131F68 consisted of the native CRL-8131 (20 mg/ml) formulated in 200-mg/ml Pluronic F-68, an 8,400-MW poloxamer consisting of 80% hydrophilic polyoxyethylene. Additional stable formulations of CRL-8131 and CRL-8142, prepared at 30 mg/ml in Tween 80-ethyl alcohol solutions, were prepared as shown in Table 1 .
T. gondii. The RH strain of T. gondii is maintained by daily passage in BALB/c mice. For an experiment, tachyzoites were harvested in cold heparinized Hanks' balanced salt solution from the peritoneal cavities of passage mice injected 48 h previously with 107 RH strain T. gondii organisms and filtered through 4-,um Nuclepore filters (Nuclepore Corp., Pleasanton, Calif.) as previously described (21) . After quantitation in a hemacytometer, tachyzoites were resuspended at the appropriate infecting dose at 4°C in Hanks' balanced salt solution.
Mouse infection. Mice were infected intraperitoneally (i.p.) with the appropriate number of freshly harvested and filtered T. gondii tachyzoites suspended in Hanks' balanced salt solution. Treatment and control groups consisted of 10 mice per group. Deaths were recorded daily for 21 days. Only rarely were deaths observed after the 16th day of infection.
Statistics. Statistical analysis was performed by Fisher's exact test.
RESULTS
Time to death after RH T. gondii infection. The RH strain of T. gondii used in these studies is highly virulent for BALB/c mice. As shown in Fig. 2 , i.p. injections with >10 tachyzoites were lethal for all infected mice, and time to death correlated with dose. In our initial studies, an infecting dose of 104 organisms, representing at least 1,000 times the 100% lethal dose, was employed. In later studies, the dose was reduced to 103 or 10 in order to compare treatment doses, routes, and timing.
Aqueous preparations of native poloxamers. In our initial (Fig. 3) .
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protective (data not shown).
treatment was critical,
In the experiments whose results are shown in Fig. 7 
DISCUSSIO
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Poloxamers are thought to be among the least toxic of known nonionic surface-active agents. These poloxamers C have been synthesized to achieve a high degree of homogel:1P I /neity relative to MW and structural characteristics. Varia- 8142F1-100 tion in the absolute and relative sizes of the constituent (16, 19) . They are among the least toxic of known nonionic surface-active agents, and several 8 10 12 14 16 have been used as inactive ingredients in pharmaceutical
Days after infection preparations (19) . Certain of the large hydrophobic poloxams per kilogram) of CRLamers are potent immunologic adjuvants (7, 8, 22) , and it has ection. Experiments A and B been reported (6) Finally, although we report here that certain poloxamers may be potent anti-T. gondii drugs against multiplying tachyzoites, in order for poloxamer chemotherapy to be effective in toxoplasmic encephalitis alone or in combination with other antitoxoplasma drugs the compound must be able to cross the blood-brain barrier and target the encysted bradyzoites as well as tachyzoites (2) . Recent reports from Remington's group (5, 9) establish in vitro and in vivo experimental models for evaluating new therapeutic agents against T. gondii in brain cysts. Poloxamer chemotherapy must be assessed in these models, and additional pharmacokinetic data are required to custom-design poloxamers to be used alone or in combination with an existing anti-T. gondii drug.
